chrisvoncsefalvay/vaers-outcomes huggingface dataset:
For about 2 hours, symptoms included nothing more than pain and swelling in and around the injection site. After 2 hours, symptoms included achy, painfully swollen joints in the hips, back, shoulders, and knees. Fever began to rise. Chills. After 3 hours, symptoms included dizziness and blurred vision, nausea, and the aforementioned symptoms. After 5 hours, symptoms included stomach and head migraines. Fever continued to rise. Inability to stand due to intense vertigo, For the next 8 hours, symptoms included feverish dreams, severe vertigo, cold sweat, chills, diarrhea, nausea, further inflammation of joints, backache, confusion, and throwing up in the mouth. The next morning, symptoms slowly declined. For the following week, upset stomach, severe vertigo, and dizzy headache remained.  Remaining symptoms 1 month later include dizziness and headache. Possibly unrelated remaining symptoms include decreased nerve sensitivity in the lower legs, especially left leg (never noticed before the vaccine, ability to feel pain in leg has declined, and as a dancer, the patient noticed this).
Patient complained of a rash on both arms and neck with light headedness and shortness of breath approximately 30 minutes after receiving Hepatitis B vaccination. Went to ER and was given Benadryl. (Did not receive word of reaction until today.)
Flu like symptoms, severe phyiscal pain all over. The pain still remains in my arms (not joints) and thighs.  Lately my neck is being effected also.
Narrative:  68 yo male found deceased at home by his family on 6/24/2021. Pt had received covid vaccines from pharmacy on 2/16/21 & 3/21/21. No information available on cause of pt's death. Likely vaccines not related to pt's death given death was 3 months post most recent vaccine.
I had high fever, over 103. I had chills, sweats, body aches, diarrhea, and a headache. I was shivering so much my teeth were chattering.
As per hospital the child develop hepatic encephalopathy 2-3 weeks after given the FLUMIST and he had liver transplant after that.
Narrative:  March 8, 2021 Patient received first COVID-19 vaccine (Pfizer) and the patient reported mild averse reaction of localized facial tingling sensation above right eyebrow. It started shortly after 13:30 and ended by 13:53 without intervention. Patient received 2nd Pfizer vaccine without incident on March 29, 2021.
Pt woke up with red dots this morning at 06:45. She was afebrile. There was less than 20 spots. No treatment.
Pt had swollen right arm w/some fevers within 12 hrs of receiving Pneumovax and Flu in R arm, and Tdap in L arm. Pt took osome ibuprofen, sxs less today (3 days after incident). No resp difficulty. No drainage from wound.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age and genders. The reporter stated that, on an unspecified date, an unknown number of doses of PEDVAXHIB (dose, lot#, expiration dates not provided) that were stored at 48 degrees F for 20 minutes, then exposed to 47 degrees for 9 minutes have been administered. No adverse effects were reported. Follow up information has been received on 22-JUL-2014 from a receptionist. The reporter stated that there were two different lot numbers of PEDVAXHIB that were included in the temperature excursion: Lot # J016188, expiration date: 02-OCT-2016 and lot # J015437, expiration date: 09-OCT-2016. The receptionist did not have any additional information to share with Merck. Follow-up information has been received from the registered nurse who provided patients details. This report refers to a 18 months old infant patient of unknown gender. On 17-JUN-2014 the patient was vaccinated with a dose of PEDVAXHIB (dose and route were not reported, lot # J016188, expiration date 02-OCT-2016) that was improperly stored. No adverse effects were reported. This is the one of several reports received from the same reporter. Additional information is not expected.
PATIENT REPORTS ONSET OF MIGRAINE HEADACHE TYPE SYMPTOMS BEGINNING DAY FOLLOWING IMMUNIZATION (DATE OF IMZ, 1/22/21, ONSET OF SYMPTOMS 1/23/21). PATIENT VERBALLY REPORTED SYMPTOMS OVER TELEPHONE EVENING OF 1/26/21 INDICATING THE HEADACHE HAD BEEN ON/OFF SINCE SATURDAY 1/23/21.  RECOMMENDED PATIENT CONTACT HER PCP FOR FURTHER FOLLOW UP.
Headache; This case was reported by a physician via call center representative and described the occurrence of headache in a 29-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number TG597, expiry date 9th March 2021) for prophylaxis.   In March 2019, the patient received Boostrix. In March 2019, immediately after receiving Boostrix, the patient experienced headache. On an unknown date, the outcome of the headache was not recovered/not resolved.   It was unknown if the reporter considered the headache to be related to Boostrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received dose of Boostrix and had experienced a headache since the dose was administered. The reporter consent to follow up.
Based on additional information received on 12-NOV-2014 and 17-NOV-2014 from health care professional, this case is considered as medically confirmed. Initial report received from a non-healthcare professional on 20 OCTOBER 2014. An elderly male patient, concomitant medications were not reported, had received a dose of INFLUENZA (batch number, lot number, expiry date and route of vaccination was not reported) in to the arm, on an unspecified date two weeks ago. The patient had received flu shot two years ago and two months later got the flu. The patient did not have any testing to determine the strain and was treated with TAMIFLU. The patient had arthritis in the shoulder (pointed to his left shoulder).  It was reported that the patient had received the flu vaccine "two weeks ago" administered it too high "right into the joint". The patient could not move his arm and has been going to physician therapy for it. Corrective treatment and laboratory data were not reported. At the time of this report the outcome of the adverse event was unknown. Follow-up information received from the healthcare professional on 12 NOV 2014 and 17 NOV 2014. The patient had previously received FLUZONE 2012-2013 to SEP 2012, FLUZONE 2013-2014 on 18 SEP 2013, FLUZONE QUADRIVALENT 2014-2015 on 26 SEP 2014, PNEUMOVAX23 DEC 2003, ZOSTAVAX in OCT 2009 and TETANUS-DIPTHERIA TOXOID, ADULT (TD) in APR 2006. HPI was not improved with the use of NAPROXEN. On 1 MAR 2013, the patient had problems with allergic rhinitis, cause unspecified. Aortic value disorder, esophageal reflux, impaired fasting glucose, other and unspecified hyperlipidemia, other psoriasis, sensorineural hearing loss, bilateral and unspecified essential hypertension. The patient had allergies to CEFZIL. The patient had received following corrective treatments. On 3 JAN 2013, UROXATRAL 10 mg tablet, extended release capsule orally and aspirin 81 mg tablet orally. On 6 JUNE 2014, received MECLIZINE 25 mg table 1 orally, on 14 MARCH 2014 the patient had received FLONASE 50 mg per inch spray NAS, 3 refills; VERELAN PM 300 mg/24 hours capsules, extended release orally, LIPITOR 80 mg table orally; NEXIUM 20 mg delayed release capsule orally; NAPROSYN 500 mg tablets 1 tablet orally on 1 JULY 2014. The patient had stomach "upset" after PM dose of NAPROXEN. The vital signs of the patient are as follows: Weight 208.0 lb; body temperature 98.6 degrees F, Blood pressure 128/60 lying down. The patient had received Mobic SIG 15 mg tablet 1 orally. List of documents held by sender: none.
From initial information received on 14Jun03 from physician regarding an adverse event occurring. It was reported that a 22 year old male pt received a YF VAX vaccination on 13Jun03, route, site were not reported. Reportedly sometime after the vaccination that same day, the pt developed a rash on both arms and on trunk of body, as well as subjective dyspnea, resp 18. The recovery status of this pt is currently unknown.
Received injection approximately 3pm, around 10pm I had 100F temperature with very sore injection site, but no other symptoms. By 10am next morning, normal body temperature with sore injection site.
NO INITIAL REACTION IN FIRST 20 MINUTES AFTER HER FIRST EVER FLU SHOT.  HOWEVER, ABOUT 40 MINUTES LATER, SHE NOTICED SWELLING IN HER THROAT.  SHE TOOK A BENADRYL PILL & 15 MIN LATER THE LUMP IN HER THROAT STAYED, BUT DID NOT WORSEN- THEN IT DECREASED TO NORMAL WITHIN 1-2 HOURS.  ON MONDAY, 11/12/12, SHE DEVELOPED CHILLS, FEVERISH, SINUS CONGESTION & PURULENT DRAINAGE WHICH LASTED FOR 2 WEEKS & THEN SPORADIC.  THE NEXT DAY 11/13/12, SHE HAD SEVERE DIARRHEA WHICH LASTED 12 DAYS.
pt exp sz;APAP given  4PM & @ 740PM devel stiffness of body lasting for 1min followed by limpness;called 911 by the time paramedics came pt was waking up;taken to ER & checked out;fever per hx;t104.7R post sz;devel croup & cough & OM;
Patient developed a pink, fine rash on trunk and arms that was like a sunburn. Patient noted to have an allergic reaction.
Vaccine was given on 7/12/21 at around 3:00pm and parent states that by that evening the patient was experiencing  nausea. There was also redness, warmth, swelling at site of vaccine (Left Deltoid). Symptoms ended 11 days later on 7/23/21
onset of muscle aches, joint pain, dizziness, fever off and on, chills, generalized weakness that onset less then 24 hours after receiving the vaccine. symptoms were worse, pretty constant on Thursday 11/21/19 and Friday 11/22/19 since the 21st and 22nd spike in sleep apnea episodes, c-pap machine is recording 60-70 apnea episodes per hour, this is very unusual, prior to the vaccine had average recordings of 20-25 episodes per hour.  lack of energy since vaccine administration
The pharmacist who administered the vaccine injected it into the subcutaneous tissues of the left deltoid region instead on intramuscularly into the deltoid.  The injection site and the surrounding have a deep tissue injury resulting in a hematoma and erythema.
pt recvd vax; pt devel severe myalgias w/ stiffness & soreness of neck, shoulders & upper back, as well as soreness at inject site w/ 1st dose; when pt recvd 2nd dose, devel same symptoms but 50% less intense;
Rash on the left side of my arm that started at the injection site down to my elbow.  I also have a bruise appear on the right side upper back and have soreness in my right Shoulder.
Confusion; irritability; nightmares; disorientation; This case was reported by a consumer via call center representative and described the occurrence of confusion in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included duloxetine hydrochloride (Cymbalta) for drug use for unknown indication.   On 5th August 2021, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On an unknown date, the patient started Cymbalta 60 mg twice daily (120 mg daily). On 7th August 2021, 2 days after receiving Shingrix, the patient experienced confusion, irritability, nightmare and disorientation. The action taken with Cymbalta was unknown. On an unknown date, the outcome of the confusion, irritability, nightmare and disorientation were not recovered/not resolved.   It was unknown if the reporter considered the confusion, irritability, nightmare and disorientation to be related to Shingrix.  Additional details were provided as follows: The case reported by the patient's brother. The patient received the 1st dose of Shingrix and in her left arm for the past 4 nights before reporting date the patient had confusion, irritability, nightmares, and disorientation. The patient was also taking Cymbalta 60mg morning and evening at 5pm which was not a new medication for the patient and she recently had a dose increase from 30mg to 60mg. It was unknown if reporter considered confusion, irritability, nightmares, and disorientation to be related to the Cymbalta use. The reporter consented to follow up.
HPI: Referred to hospital after visiting pcp 8/30 for fatigue; pcp ordered chest xray which showed bilateral pneumonia and dehydration PMH: hypertension, hypothyroidism, GERD, presbycusis, hx of colon cancer, urinary incontinence, anemia, seasonal allergies, peripheral neuropathy, hyperliidemia, vit d deficiency, dementia, hx of smoking. Allergies: SOMA, darvocet, penicillins, wellbutrin Tested positive for COVID upon arrival; given supplemental O2 but continued to decline. Family made arrangements to transition to hospice. However, pt passed away the morning of 09/16/2021 before she could be transitioned to hospice care.
Information has been received from a registered pharmacist concerning a 65 year old female who on 15-JUN-2010 was vaccinated with ZOSTAVAX (Merck). On approximately 17-JUN-2010 (also reported as 1.5 to 2 days after the vaccination) the patient developed a 1.5 inch area of inflammation and swelling around the injection site. The patient contacted the pharmacist to seek medical attention. At the time of the report, the patient had not recovered. This report was amended. The onset date was changed from 18-JUN-2010, day approximately to 17-JUN-2010. Additional information has been requested.
Pain and weakness in arm continues after 1.5 weeks, doesn?t respond to ibuprofen or acetaminophen. Feels like a bad bruise with pain radiating up the shoulder, no marks, redness, or swelling.
Swollen, red arm at injection site 80mmX55mm  Narrative:  Staff member felt symptoms bothered her enough to report: Swollen, red arm at injection site 80mmX55mm
Suspected vaccination failure; Got shingles; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: This case was reported by patient him/herself. The age at vaccination was not reported. The patient received Shingles vaccine and still got shingles. This case was considered as suspected vaccination failure, since the details regarding the completion of the primary immunization schedule, time to onset for event and laboratory confirmation of shingles were not provided.
Headache, Myalgia, Fever, PAIN AND SWELLING AT INJECTION SITE Narrative:
Sore throat; Dry mouth; This spontaneous case from the Regulatory Authority was received on 12-Oct-2022 from a physician via Pfizer (reference number: 202201191501), with additional information received via Med Communications on 13-Oct-2022 (reference number: SEQW22-04455) and on 17-Oct-2022 (reference number: SEQW22-04582) and retrieved on 14-Oct-2022 from Vaccine Adverse Event Reporting System (VAERS) (reference number: 2465271-1) (being processed together), and concerned an adult male patient of an unspecified age.  The patient's medical history and concomitant medications were not reported. The patient's historical vaccine included three doses of Covid-19 vaccine (brand not specified), two doses received on an unspecified date and  third dose (booster) received on an unspecified date in Oct-2021, all used for Covid-19 immunisation.  On 23-Sep-2022, the patient was vaccinated with Flucelvax Quadrivalent (influenza vaccine inact sag 4v; dose: 0.5 ml; anatomical location: deltoid; route of administration: not reported) for immunisation and prevention of Influenza disease. The batch number was not reported. The patient has not experienced COVID prior to the vaccination.  On the same date, the patient was vaccinated with non-company co-suspect Pfizer-BioNTech COVID-19 Vaccine (tozinameran; dose: reported as '4 (booster)'; route of administration: intramuscular; anatomical location and indication: not reported). The batch number was not reported.  On 24-Sep-2022, 24 hours after receiving Flucelvax Quadrivalent and co-suspect Pfizer-BioNTech COVID-19 Vaccine, the patient experienced persistent and severe sore throat associated with dry mouth. No fever or exudates. The patient was taking ibuprofen with minimal relief.  On an unspecified date in 2022, the patient underwent COVID-19 antigen test two times and nasal swab, and the results were negative.  On an unspecified date in Sep-2022, the patient recovered from the events. As reported, they lasted about six days and resolved.  The reporter did not provide a causality assessment.  The case was assessed as non-serious.  Company comment: A patient of unreported age experienced oropharyngeal pain and dry mouth one day after receiving the suspect product Flucelvax Quadrivalent and co-suspect Pfizer-BioNTech COVID-19 Vaccine. Despite confounding by co-suspect vaccine, causal role of the suspect product cannot be excluded. Therefore, causality for the reported events is assessed as possibly related due to plausible temporal relationship.; Sender's Comments: A patient of unreported age experienced oropharyngeal pain and dry mouth one day after receiving the suspect product Flucelvax Quadrivalent and co-suspect Pfizer-BioNTech COVID-19 Vaccine. Despite confounding by co-suspect vaccine, causal role of the suspect product cannot be excluded. Therefore, causality for the reported events is assessed as possibly related due to plausible temporal relationship.
Pt says she has a swollen, warm red area on her arm below the injection site.  She was concerned and went to the local clinic where they told her she was having an allergic reaction to the preservatives in the Flublok she had given the day before
After 24 hours hearing in left ear was diminished and has not resolved.; This is a spontaneous report from a contactable consumer. A 52-years-old female patient received her first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 06Apr2021 15:45 (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunization (Age at vaccination: 52 years). Medical history was reported as none. The patient's concomitant medications were not reported. On 07Apr2021, 08:00, after 24 hours hearing in left ear was diminished and has not resolved. The patient did not received any treatment for the event. Patient was not pregnant The patient did not have COVID prior vaccination. The patient did not test for covid post vaccination. Outcome of the event was not recovered.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Information has been received from a physician assistant concerning a 22 year old female patient with no pertinent medical history and drug allergy who received the three dose series of RECOMBIVAX HB injection (dosage not provided) at another practice as follows: first dose (lot#: 635270/0317K) (Expiration: 10-JAN-2003) on 25-APR-2000, second dose (lot#: 637372/1324K) (Expiration: 18-AUG-2003) on 27-NOV-2000 and the third dose Thimerosal Free (lot#: 640324/0674L) (Expiration: 02-APR-2004) on 18-JUL-2001. There was no concomitant medication. On 04-AUG-2011, a titer "was not 100%". One additional dose of RECOMBIVAX HB 1.0 ml was given on 16-AUG-2011 and she would probably receive another dose now on 20-SEP-2011. The patient sought medical attention in office. At the time of the report, the patient had not recovered. Follow up information has been received from the physician assistant concerning the 11 year old student with no pertinent medical history and drug allergy who were vaccinated intramuscularly with three doses of RECOMBIVAX HB injection (dosage not provided) as follows: first dose (lot#: 635270/0317K) (Expiration: 10-JAN-2003) on 25-APR-2000 in the right arm, second dose (lot#: 637372/1324K) (Expiration: 18-AUG-2003) on 27-NOV-2000 in the left arm and the third dose Thimerosal Free (lot#: 640324/0674L) (Expiration: 02-APR-2004) in the left arm on 18-JUL-2001. It was reported that the patient did not seek medical attention. On 04-AUG-2011, the patient had blood drawn to check for immunity to the previously given hepatitis B series. The results showed that the patient did not have immunity to hepatitis B virus. On the same day, serum hepatitis B surface antibody quantitative test with the result of 7 mIU/ml, and hepatitis B core antibody total test with the result of non-reactive. The patient was not illness at the time of vaccination. At the time of the report, the patient had recovered. No further information is available.
Onset occurred two weeks after the first dose. Dizziness, shortness of breath, weakness, extreme anxiety, vertigo and racing heartbeat; muscular inflammation spasms and knotting specifically in upper back shoulders and neck; body aches and joint pain; sleep disruptions.
The next day I had a low grade fever of 99.9, body aches, and chills.  My left arm was significantly sore all day, pain from my shoulder to elbow and into my armpit/chest.  On Wednesday, Jan 20th, I noticed a red mark, oval in shape, about 4 inches from the injections site that became warm to touch.  During Wednesday and Thursday, the red mark got larger, wrapping around the outside of my arm and slightly swelled.  It is still warm to touch but not as red today (Monday 1/25). I have applied ice to it twice a day for 20 minutes at a time.
Patient developed shingles with neuropathic pain.  Continues with neuropathic pain in foot/ankle since then.
Grandmal sz x 15-20 seconds, witnesed; followed by vomiting; hospitalized overnight w/reported nl EEG, EKG & Cat Scan;
Generalized maculopapular erythematous rash, quite pruritic.  Present for 3.5 d at time of clinic visit. Given Kenalog/Celestone for pruritis
received his 1st dose / in 11/2018, and never came back for the 2nd one; This case was reported by a nurse via call center representative and described the occurrence of incomplete course of vaccination in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received in November 2018).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time of repoting the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. The reporter consented to follow up.
On March 3rd when I woke up, I did not feel right, I was dizzy, but I went to work anyway; my stomach was not good either, but on the 5th, I was so ill, I had diarrhea, low fever, very dizzy, I had the COVID test at home and it was positive. I called school on Monday, and I stayed home, it lasted 3 three weeks.